ArticleAbdominal radiology (New York)2026
Implementation of a biparametric prostate MRI protocol with a recall system for intravenous contrast: an analysis of recall rates and comparison of PI-RADS category distribution.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Successes and challenges in developing a magnetic resonance imaging-transrectal ultrasound machine fusion prostate biopsy service.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2026Review
- Cancer Detection and Surveillance Pathways with Abbreviated MRI in the Prostate, Pancreas, and Liver: A Risk-Stratified Narrative Review.Current oncology (Toronto, Ont.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe prostate magnetic resonance imaging (MRI) protocol changed from a contrast multiparametric MRI (mp-MRI) to a non-contrast biparametric (bp-MRI) protocol at a single centre. This study describes the recall rate, median time to recall, and PI-RADS distribution pre-/post-implementation.
methodsThis retrospective descriptive study involved a consecutive sample of all 3 Tesla (3T) prostate bp-MRIs following the protocol change (01April2023-23May2024) to determine the proportion of bp-MRIs recalled, the indications for recall, and the median time until recall MRI (Part 1). A subset of these prostate MRIs was compared to a consecutive sample immediately prior to the change in protocol to compare the distribution of PI-RADS categories (Part 2). The distribution of MRI reporting frequency by radiologists was compared pre-/post-implementation (Part 2). INCLUSION CRITERIA: 3T bp-MRI protocol, out-patient, male, and ≥ 18 years of age.
resultsA total of 554 prostate bp-MRIs took place during the study period, 547 (96.8%) were included. Of the 547 subjects, 36 (6.6%) were recalled for intravenous (IV) contrast. Most recalls were for PI-RADS 3 reassessment (33/36, 91.7%). PI-RADS categories were upgraded from 3 to 4 in 16/33 (48.5%) subjects. The median time between initial and recall MRI was 35 days. There was no statistically significant difference in the distribution of PI-RADS categories before (n = 225) and after (n = 225) implementation of the bp-MRI protocol (X
conclusionA small proportion (6.6%) of bp-MRI subjects were recalled for contrast reassessment and the majority of those (91.7%) were for PI-RADS 3 reassessment. There was no statistically significant difference in the distribution of PI-RADS categories following implementation of the bp-MRI protocol. Implementation of a bp-MRI protocol at a single centre reduced patient exposure to IV contrast while not changing PI-RADS distribution.
Indexed as
Identifiers
41065830What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.